Skip to main
ATAI
ATAI logo

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 17 analyst ratings
Strong Buy
Strong Buy 71%
Buy 24%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

ATAI Life Sciences NV exhibits a promising outlook due to its advancing pipeline of psychedelic-based therapies, specifically with BPL-003, which has demonstrated potential for durable treatment effects in alcohol use disorder (AUD). Recent data indicates that BPL-003 may achieve a significant and lasting impact on patient outcomes, as evidenced by half of the patients maintaining complete abstinence for up to 12 weeks post-treatment. Additionally, the favorable tolerance profile and sustained antidepressant effects observed in related studies bolster the company's position in the mental health treatment landscape, making it a noteworthy candidate for future investment consideration.

Bears say

ATAI Life Sciences NV is currently navigating a challenging financial landscape, with reported substantial operating losses that raise concerns about the sustainability of its business model. Furthermore, the company relies heavily on the success of its clinical trials and the potential market uptake of its psychedelic-based therapies, which remain speculative and uncertain given the evolving regulatory environment. Additionally, limited cash reserves may hinder ATAI's ability to fund its ongoing research and development initiatives, impacting its long-term growth prospects.

ATAI has been analyzed by 17 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 24% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 17 analysts, ATAI has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.